Welcome to the Seattle Genetics grant management system. Use this online system to request support from Seattle Genetics, Inc. for Independent Medical Education (IME), Investigator-Sponsored Trials (IST) Charitable Grants or Preclinical Proposals.

Seattle Genetics is committed to conducting business in compliance with all Seattle Genetics' policies, American Medical Association ("AMA") Guidelines on Gifts to Physicians, the AMA Ethical Opinion on Independent Medical Education, the Pharmaceutical Research and Manufacturers of America ("PhRMA") code on Interactions with Healthcare Professionals, the Accreditation Council for Independent Medical Education ("ACCME") Standards for Commercial Support, the U.S. Food and Drug Administration ("FDA") regulations and guidance, the U.S. Department of Health and Human Services' Office of Inspector General ("OIG") guidance and all applicable federal and state laws and regulations.

To begin the request process, please log in to our system using your User ID and Password on the left side of the screen. If you are a first time user, please click on the link below "Need a User ID?" to begin the registration and application process.

Independent Medical Education Grants

Seattle Genetics is committed to supporting innovative, high quality, independent accredited and unaccredited medical education for healthcare professionals that addresses unmet medical needs, fosters clinical excellence, and improves health outcomes in areas of interest to our company. A program supported by an educational grant must be for scientific and educational purposes only and not considered a commercial or corporate sponsorship. For more information on independent medical education grants, please see ourProgram Overview .

Call for Grant Applications
CGA HL 1701 - Hodgkin Lymphoma

Investigator-Sponsored Trials

Our Investigator-Sponsored Trials (IST) program provides support for external clinical research that advances medical and/or scientific knowledge about our products to enhance patient care. Our current IST portfolio supports Hematology/Oncology and Immunology indications, though with strong scientific rationale other indications may be considered.

The objective of the Seattle Genetics IST program is to provide funding and/or study drug for clinical research that will:

  • Address unmet medical need with new scientific data; and
  • Support pilot studies that explore the feasibility of new treatments.

For additional information regarding support for ISTs, please see ourProgram Overview . To discuss your proposed research or for questions about our process, please contact your regional Medical Science Liaison (MSL) or email us atIST@seagen.com . For assistance in identifying the MSL for your territory, please contactIST@seagen.com .

Brentuximab Vedotin Clinical Studies Areas of Interest

  • Immuno-oncology combinations
  • Novel approaches in frontline HL
  • Novel CTCL approaches
  • Patients previously treated with brentuximab vedotin
  • Combinations with standard of care agents
  • CD30+ non-Hodgkin lymphomas

Brentuximab Vedotin Preclinical Studies Areas of Interest

  • Post-dose studies (banked tumor tissues, serum and/or plasma)
  • Tumor microenvironment (in vivo or in vitro)
  • Activity with Immuno-oncology agents

Proposals outside of these areas of interest may be considered with strong scientific rationale.

Charitable Grants

Seattle Genetics may fund a limited number of requests from non-profit tax-exempt organizations under section 501(c)(3) of the Internal Revenue Code for programs that relate to hematology/oncology and provide patient education, patient advocacy or patient support. Although we receive numerous requests for support, we are able to fund a limited number. Completed submissions that meet our review criteria and are submitted with sufficient notice will be reviewed and considered for funding. For more information on our charitable grants, please see ourProgram Overview .

All IME and charitable requests for funding, including all required supporting documentation, must be submitted to Seattle Genetics at least 60 days prior to your event date or 60 days prior to the date you require a decision (whichever is earlier).

Preclinical Proposals

Seattle Genetics considers requests for preclinical research using brentuximab vedotin (SGN-35, ADCETRIS). Requests for materials transfer or sponsored research will be considered, with a limited number of projects supported each year. To discuss your proposal prior to submission, please contact your MSL directly. For assistance in identifying the MSL for your territory, please contactIST@seagen.com

For all grant types please note:

  • You can save your request submission at any stage of the process and return to complete your request application at a later time.
  • Seattle Genetics will generally review your request for completion, clarity, and compliance within 45-60 days of submission.
  • You will receive an email notification upon approval or denial of your request.
  • If approved, funding is conditioned on the requirement to provide budget reconciliation within 90 days following completion of your event, activity or IST.
  • If funding was not used for the approved purpose and a refund is due to Seattle Genetics, you will have 30 days after submitting your reconciliation to submit the refund.
  • Failure to complete the reconciliation and/or submit the refund within the allocated timeframes may result in your inability to submit future requests for funding, in addition to any rights or remedies available to Seattle Genetics.